What are the recommended steps for diagnosing and managing Charcot‑Marie‑Tooth disease, including genetic testing, rehabilitation, pain control, and counseling?

Charcot-Marie-Tooth Disease: Diagnosis and Management

Begin with electrodiagnostic studies (EMG/NCS) to classify the neuropathy as demyelinating versus axonal, then proceed with sequential genetic testing starting with PMP22 duplication for demyelinating forms, as this stepwise approach maximizes diagnostic yield while minimizing cost. 1

Diagnostic Algorithm

Step 1: Clinical Assessment and Family History

Obtain a comprehensive three-generation family history to determine inheritance pattern (autosomal dominant, autosomal recessive, X-linked, or sporadic). Look specifically for:

• Age of symptom onset (typically childhood to early adulthood)
• Progressive distal weakness and muscle atrophy
• Foot deformities (pes cavus, hammer toes)
• Distal sensory loss
• Absent or reduced deep tendon reflexes
• Pattern of affected family members

Critical pitfall: 30% of mutations are de novo, so absence of family history does not exclude CMT 1. Maintain high clinical suspicion even in sporadic cases.

Step 2: Electrodiagnostic Studies (EMG/NCS)

This is the critical branching point that determines your genetic testing strategy. Perform nerve conduction studies to classify as:

• Demyelinating (CMT1): Motor nerve conduction velocity <38 m/s in upper limbs
• Axonal (CMT2): Motor nerve conduction velocity >38 m/s with reduced amplitudes
• Intermediate: Values between these ranges

Step 3: Sequential Genetic Testing

For Demyelinating Neuropathy with Autosomal Dominant Pattern:

1. First-tier test: PMP22 duplication (CMT1A) - yields 54-80% positive results in this population 1
2. If negative and pedigree uninformative for X-linked: Test GJB1/Cx32 (CMTX) - accounts for 12% of all CMT 1
3. If still negative: PMP22 point mutations (2.5% yield) and MPZ mutations (5% yield) 1
4. Consider next-generation sequencing panel for remaining cases 2

For Axonal Neuropathy with Autosomal Dominant Pattern:

1. First-tier test: MFN2 mutations (CMT2A) - accounts for 33% of CMT2 cases 1
2. If pedigree uninformative: Consider GJB1/Cx32 testing (can present with axonal pattern) 1
3. Next-generation sequencing for other CMT2 subtypes 2

For X-linked Pattern (no male-to-male transmission):

• Test GJB1/Cx32 first regardless of demyelinating or axonal pattern 1

Genetic testing provides 100% specificity (no false positives) and high sensitivity for established pathogenic mutations 1. Novel mutations may require specialized center interpretation.

Management Approach

Current Treatment Reality

No disease-modifying pharmacological treatments are currently approved for CMT 2, 3. Management focuses entirely on symptomatic and supportive care.

Rehabilitation and Physical Therapy

Initiate early and maintain throughout disease course 2:

• Individualized exercise programs to maintain strength and flexibility
• Stretching exercises to prevent contractures
• Balance and gait training
• Aerobic conditioning within patient tolerance

Orthotic Management

• Ankle-foot orthoses (AFOs) for foot drop and ankle instability
• Custom footwear for foot deformities
• Assistive devices (canes, walkers) as needed for mobility

Orthopedic Surgical Interventions

Consider early assessment for conservative surgeries 2:

• Tendon transfer procedures for foot drop
• Correction of pes cavus deformity
• Stabilization procedures for severe ankle instability
• Timing is critical: intervene before fixed deformities develop

Pain Management

Address neuropathic pain when present (though less common than in acquired neuropathies):

• Gabapentin or pregabalin as first-line agents
• Duloxetine or tricyclic antidepressants as alternatives
• Physical modalities (TENS, desensitization techniques)

Fatigue Management

• Energy conservation techniques
• Pacing strategies
• Occupational therapy assessment for adaptive equipment

Comorbidity Screening

Monitor for depression (47% prevalence reported) 4 and gastrointestinal issues (most common comorbidity in Chinese cohort) 4.

Genetic Counseling

Provide comprehensive counseling regarding:

• Inheritance pattern and recurrence risk (50% for autosomal dominant, 25% for autosomal recessive)
• Variable expressivity even within families
• Prenatal and preimplantation genetic diagnosis options
• Implications for family members and cascade testing

Follow-Up Strategy

Follow-up is exclusively clinical; routine ancillary testing is not necessary 2:

• Annual assessments for mild disease
• More frequent monitoring (every 6 months) for rapidly progressive or severe cases
• Focus on functional status, pain, mobility, and quality of life
• Repeat electrodiagnostic studies only if diagnostic uncertainty or atypical progression

Future Therapeutic Landscape

While not yet available, promising approaches in development include 3, 5:

• Govorestat for CMT-SORD: Interim analysis shows promise as potentially first approved CMT drug
• PMP22 gene silencing for CMT1A: Approaching clinical trials
• Gene therapy for CMT2S: Already in clinical trial phase
• HDAC6 inhibitors in preclinical development

The diagnostic delay averages 3.8 years from symptom onset to genetic confirmation 4, emphasizing the importance of early recognition and appropriate sequential testing to expedite diagnosis and enable proper counseling and supportive care initiation.